Twenty-six states and the District of Columbia expanded Medicaid in January 2014 pursuant to the Affordable Care Act (ACA); 24 states did not. This created an opportunity to examine the impact of Medicaid expansion on the number of Medicaid patients with newly identified diabetes among enrollees (19-64 years of age) who had laboratory testing through Quest Diagnostics.
states could decide whether they would accept the conditions to expand Medicaid (1) . Twenty-six states and the District of Columbia ("expansion states") agreed to expand Medicaid; 24 states did not (2) . This division of states created an opportunity to examine the impact of Medicaid expansion on specific health metrics, such as detection of disease, using the Quest Diagnostics database. In this Quest Diagnostics Health Trends study, we used deidentified patient data to assess changes in identification of newly identified laboratory-defined diabetes after implementation of Medicaid expansion.
We selected diabetes as an indicator because it is a common medical condition affecting ;28-29 million Americans and has a much larger population at risk (3) . In addition, aggressive prevention and treatment programs have been shown to improve outcomes (4) . Clear definitions have been established that are amenable to analysis using laboratory measurements in a large databasecentered epidemiological study (5) . Finally, any observations derived from such an analysis are likely to be applicable to other common chronic medical conditions.
RESEARCH DESIGN AND METHODS
Quest Diagnostics maintains the largest private clinical laboratory database in the U.S. Consisting of deidentified data on nearly 2 billion patient encounters since 2000, the database provides laboratory information on the vast majority of conditions and diseases affecting the U.S. population. Quest Diagnostics has approximately 150 million patient encounters annually with individuals from all states and the District of Columbia. The overall testing volume declined slightly in the study period (first half of 2014) compared with the control period (first half of 2013). This Quest Diagnostics Health Trends study was determined to be exempt by the Western Institutional Review Board.
The Quest Diagnostics database was queried for patients 19-64 years of age meeting our laboratory criteria for newly identified diabetes in the preMedicaid expansion control period (January-June 2013) or the postexpansion study period (January-June 2014). Newly identified diabetes was defined as having an ICD-9 diagnosis code of 250.x (diabetes) or a hemoglobin A 1c of .6.4% (46 mmol/mol) within the control or study period and the absence of both in the preceding calendar year (January-December 2012 for control period and January-December 2013 for the study period). Importantly, all patients included in this analysis had to have had at least one test through Quest Diagnostics in the preceding calendar year. This was to assure that we identified patients with only newly identified diabetes on the premise that patients with diabetes should receive hemoglobin A 1c testing and are likely to have been assigned an ICD-9 code of diabetes in the preceding year.
Patients were categorized as being Medicaid enrollees if they were enrolled in Medicaid at the time diabetes was diagnosed having a hemoglobin A 1c .6.4% (46 mmol/mol) or an ICD-9 code of 250.x (diabetes) in the control period or study period. Medicaid, including managed Medicaid, was listed on the test requisition as one of the payers.
The residence (state or District of Columbia) of each patient was based on the address provided for the patient at the time of testing that was used for categorization of the patient as having newly identified diabetes.
Hemoglobin A 1c testing was performed using the Roche Cobas Integra (Indianapolis, IN), which is National Glycohemoglobin Standardization Program certified. Statistical significance of comparisons was tested using Pearson x 2 test to assess the difference between proportions. Analyses were performed in SAS 9.4 (SAS Institute, Inc., Cary, NC).
RESULTS
A total of 434,288 patients from all 50 states and the District of Columbia met our criteria for newly identified diabetes. Demographic features (age and sex distributions) of patients remained stable between the control and study periods ( Table 1 Overall, we observed a 1.6% increase in newly identified diabetes from the control period to the study period ( Table 2) . In our analysis, we focused on patients who were enrolled in Medicaid at least once during the control or study periods and for whom data were available establishing the absence of diabetes (by ICD-9 code or hemoglobin A 1c test result) in the preceding calendar year. A total of 26,237 Medicaid-enrolled patients were newly identified with diabetes in the control period vs. 29,673 Medicaid-enrolled patients in the study period: an increase of 13% (Table 2 ). We examined the data for other (non-Medicaid) patients in both periods as well to have a comparison group with which to contrast the observations in Medicaid patients. The number of patients with newly identified diabetes among other patients increased by only 0.03% from the control (n = 189,161) to the study (n = 189,217) periods ( Table 2 ).
The Medicaid patients were then analyzed after assignment into the two categories (expansion states versus nonexpansion states) ( Table 2 ). Within the expansion states, 14,625 patients were classified as having newly identified diabetes in the control period vs. 18,020 patients in the study period: an increase of 23%. In the nonexpansion states, by contrast, 11,612 patients were classified as having newly identified diabetes in the control period vs. 11,653 patients in the study period: an increase of 0.4% ( Fig. 1 ).
The number of other patients with newly identified diabetes decreased by 2.2% within the expansion states between the control (106,524) and study (104,133) periods but increased by 3.0% (82,637 in the control period to 85,084 in the study period) in the nonexpansion states (Fig. 1) . The overall increase in newly identified patients with diabetes was about the same magnitude in the expansion states (0.8%) and nonexpansion states (2.6%) ( Table 2) .
Patients were also categorized by sex (Table 3) and by age range (younger, ages 19-49 years, and older, ages 50-64 years) ( Table 4 ). The surge in newly identified Medicaid patients with diabetes in the expansion states was observed for each category of sex or age-group (P , 0.0001).
A potential explanation for the increase in the number of newly identified patients with diabetes is that diabetes is being diagnosed at an earlier stage of disease. Among Medicaid patients with newly identified diabetes, the mean (SD) hemoglobin A 1c was 8 The lower mean hemoglobin A 1c results with a smaller SD in the expansion states support the observation that the newly identified patients with diabetes in the expansion states are more likely at an earlier state of their disease than within the nonexpansion states. We postulate that these Medicaid patients with newly identified diabetes will experience better management of their disease than if diagnoses had been made later. This could be anticipated to lead to fewer long-term complications. For the other patient population, there was a minimal increase of 0.03% (from the control period in 2013 to the study period in 2014) in the number of patients with newly identified diabetes. There are many less dramatic differences between groups and changes observed in this study. For example, when both Medicaid enrollees and nonenrollees are considered, nonexpansion states had a greater overall increase in newly identified patients with diabetes (2.6%) than did the expansion states (0.8%). Two main factors drove this finding. First, the number of newly identified other patients with diabetes actually decreased by 2.2% in the expansion states while increasing 3.0% in the nonexpansion states. This difference is small in clinical impact, and the overall change may be compatible with data from the Centers for Disease Control and Prevention suggesting that the diabetes epidemic may be reaching a plateau (6) . Second, this difference was magnified because other patients vastly outnumbered the Medicaid patients. These observations warrant further analysis to see whether these changes are due to shifts among payers, small shifts in Quest Diagnostics business in these states, or underlying differences in the growth of diabetes in the expansion versus nonexpansion states. Of note, 9 of the 11 states (AL, GA, IN, LA, MS, NC, SC, TN, and VA) with high rates of stroke, cardiovascular disease, and obesity are represented in the nonexpansion states and may account for faster growth in new diabetes in the nonexpansion states. The other two states, AR and KY, expanded Medicaid.
The general observations were similar when analyzed by sex. For men, the change in the number of Medicaid patients with newly identified diabetes was 25.5% in the expansion states and only 4.6% in the nonexpansion states (P , 0.0001). For women, the change in the number of Medicaid patients with newly identified diabetes was 22% in the expansion states and declined 1.4% in the nonexpansion states (P , 0.0001). Women comprised 58% of patients newly identified with diabetes across both periods. Yet, the percent change in newly identified diabetes was more striking among men than women. In the other patient population, the changes were modest for both men and women in both the states with and the states without Medicaid expansion, with men always having a slightly higher rate of newly identified patients with diabetes in the study versus control periods. Two hypotheses are that women have had a more consistent pattern of medical service utility and that men are at greater risk of developing diabetes within the 19-64 age range.
In like fashion, the observations were similar when analyzed according to agegroups: younger (ages 19-49 years) and older (ages 50-64 years) patients. For younger patients, the change in the number of Medicaid patients with newly identified diabetes was nearly 15% in the expansion states; there was essentially no change in the nonexpansion states. For older patients, the change in the number of Medicaid patients with newly identified diabetes was 31% in the expansion states and increased 0.5% in the nonexpansion states (P , 0.0001). The percent change in newly identified diabetes was more striking among older patients than Our definition of newly identified diabetes reflects the limitations of our approach. We lacked clinical information and relied on the provision of ICD-9 codes from ordering physicians and hemoglobin A 1c testing performed only at Quest Diagnostics. Some of these patients may have been diagnosed previously but lacked the specified testing in the preceding calendar year or received testing from other clinical laboratories. Some patients might have had alternative explanations for an elevated hemoglobin A 1c , and in some cases, the test requisition might have been incorrectly coded by the ordering physician. Further, there are regional differences in clinical practice and access to medical care throughout the U.S. We postulate that such differences were insignificant when comparing the 26 states and District of Columbia to the 24 nonexpansion states. Overall, we believe that our findings closely approximate the actual number of newly diagnosed patients with diabetes. Another consideration is that Medicaid enrollment increased 18.5% in the expansion states that opted to accept the conditions of the ACA (5). Medicaid enrollment enlarged 4.0% in the nonexpansion states that chose not to accept Federal funds for the expansion (5). The comparison between the expansion and nonexpansion states was slightly confounded by this voluntary expansion of Medicaid enrollment. Also, some of the patients categorized as Medicaid patients in the control and study periods may have been Medicaid enrollees in the preceding calendar years.
In summary, this Quest Diagnostics Health Trends report provides insight into the impact of the national Medicaid expansion under the ACA. Medicaid expansion states had a 23% increase in newly identified Medicaid patients with diabetes compared with a year earlier; the change was 0.4% in the nonexpansion states. This large difference between expansion states versus nonexpansion states was observed in men and in women and in younger and older patients within the 19-64 age range. These observations were based on comparing only the first 6 months of Medicaid expansion under the ACA. The data suggest that new enrollees in Medicaid are being screened for diabetes and that screening was productive. Since we do not have clinical data, we cannot comment as to whether such screening was targeted using criteria such as those suggested by the American Diabetes Association (7) . The subject of screening is controversial. One trial (8) showed no mortality benefit over 5 years with the early diagnosis obtained from such screening. However, the timeline of that study was likely too short to see a mortality benefit. The U.S. Preventive Services Task Force has recently endorsed screening for type 2 diabetes for patients $45 years old and for patients with other risk factors (9) . Additional follow-up will be required to establish whether these trends continue (10) .
Our data suggest that Medicaid expansion has led to an increased number of Medicaid patients being newly diagnosed with diabetes. Beyond diabetes, the trends we observed in the current study are likely to affect diagnosis of other chronic medical conditions such as hypertension, hypercholesterolemia, and chronic kidney disease. Such a pattern has already been reported for the diagnosis of HIV (11) , where diagnosis occurred at an earlier stage among Medicaid patients in expansion states. Improved access and use of medical services may in turn lead to earlier diagnosis of associated diseases and permit earlier intervention to reduce long-term complications (12) .
